LANABECESTAT

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H28N4O
Molecular Weight	412.5267
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1CC[C@@]2(CC3=CC=C(C=C3[C@@]24N=C(C)C(N)=N4)C5=CC(=CN=C5)C#CC)CC1

InChI

InChIKey=WKDNQONLGXOZRG-HRNNMHKYSA-N

InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22-,25-,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H28N4O
Molecular Weight	412.5267
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27418961 | https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html

AZD-3293 camsylate wider known as Lanabecestat camsylate, a salt of Lanabecestat, a drug that was invented for the treatment of Alzheimer's disease. Lanabecestat inhibits beta-secretase 1 cleaving enzyme (BACE1) thus preventing the buildup of beta-amyloid and help stop the progression of Alzheimer's disease. The drug was in phase III clinical trials, but studies were discontinued because of recommendations by an independent data monitoring committee (IDMC). IDMC concluded that all trials, in early Alzheimer’s disease, and in mild Alzheimer’s disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-secretase 1 21 Target ID: P56817\|\|\|Q9UJT5 Gene ID: 23621.0 Gene Symbol: BACE1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27418961	Inhibitor 8504		0.4 nM [Ki]

C_max

Value	Dose	Co-administered	Analyte	Population
314 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27767991/	50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LANABECESTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
361 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27767991/	50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LANABECESTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2820 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27767991/	50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LANABECESTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3960 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27767991/	50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LANABECESTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27767991/	50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LANABECESTAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27767991/	50 mg 1 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		LANABECESTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.	2016	27418961
Compounds and Their Use as BACE Inhibitors: Patent Highlight.	2012-11-08	24900397

Sample Use Guides

In Vivo Use Guide

Lanabecestat (AZD3293) 20 milligrams (mg) given orally once daily for 104 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:56:17 GMT 2025` Edited by `admin` on `Wed Apr 02 06:56:17 GMT 2025`
Record UNII	X8SPJ492VF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LANABECESTAT

Official Name

English

lanabecestat [INN]

Preferred Name

English

DISPIRO(CYCLOHEXANE-1,2'-(2H)INDENE-1'(3'H),2''-(2H)IMIDAZOL)-4''-AMINE, 4-METHOXY-5''-METHYL-6'-(5-(1-PROPYN-1-YL)-3-PYRIDINYL)-, (1.ALPHA.,1'R,4.BETA.)-

Systematic Name

English

(1R,1'R,4R)-4-METHOXY-5''-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-- DISPIRO(CYCLOHEXANE-1,2'-INDENE-1',2''-IMIDAZOL)-4''-AMINE

Systematic Name

English

Lanabecestat [WHO-DD]

Common Name

English

LY-3314814

Code

English

(1R,1'R,4R)-4-METHOXY-5''-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDEN-1',2''-IMIDAZOL)-4''-AMINE

Systematic Name

English

AZD-3293

Code

English

LY3314814

Code

English

LANABECESTAT [USAN]

Common Name

English

AZD3293

Code

English

(1,4-TRANS,1'R)-4-METHOXY-5''-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDENE-1',2''-IMIDAZOL)-4''-AMINE

Systematic Name

English

Code System Code Type Description

NCI_THESAURUS

C170091